专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20060211863A1 Process for the preparation of opioid modulators 有权
公开(公告)号：US20060211863A1
公开(公告)日：2006-09-21
申请号：US11368564
申请日：2006-03-06
申请人： Chaozhong Cai , Wei He
发明人： Chaozhong Cai , Wei He
IPC分类号： C07D217/12 , C07D277/56 , C07D263/34 , C07D239/02 , C07D233/61 , C07D241/36 , C07D241/02
CPC分类号： C07D233/64 , C07D233/61 , C07D401/04
摘要： The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestinal disorders.

82. 发明申请

US20050026226A1 Serum Paraoxonase 失效
标题翻译：血清对氧化酶
公开(公告)号：US20050026226A1
公开(公告)日：2005-02-03
申请号：US10932269
申请日：2004-09-02
申请人： Peter Hudson , Wei He , Steven Ruben
发明人： Peter Hudson , Wei He , Steven Ruben
IPC分类号： C12N15/09 , A61K38/00 , A61K38/46 , A61K48/00 , A61P39/00 , A61P43/00 , C07K14/47 , C07K16/18 , C07K16/40 , C12N1/21 , C12N5/06 , C12N5/10 , C12N9/16 , C12N9/18 , C12N15/12 , C12N15/55 , C12P21/02 , C12P21/04 , G01N33/53 , G01N33/567
CPC分类号： C12N9/16 , A61K38/00 , A61K48/00 , C12N9/18 , Y10S530/809
摘要： Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death.
摘要翻译：公开了人血清对氧磷酶和编码这种血清对氧磷酶的DNA（RNA）。还提供了通过重组技术生产此类多肽的方法。这些多肽的用途包括它们作为有机磷酸盐中毒的解毒剂和防止神经元细胞死亡的用途。

83. 发明授权

US06528526B1 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases 失效
公开(公告)号：US06528526B1
公开(公告)日：2003-03-04
申请号：US09675746
申请日：2000-09-29
申请人： Michael R. Myers , Wei He , Alfred P. Spada , Martin P. Maguire
发明人： Michael R. Myers , Wei He , Alfred P. Spada , Martin P. Maguire
IPC分类号： A61K3133
CPC分类号： C07D215/38 , C07D215/20 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

84. 发明授权

US5291997A Medical mailer box assembly 失效
标题翻译：医疗邮箱组装
公开(公告)号：US5291997A
公开(公告)日：1994-03-08
申请号：US926657
申请日：1992-08-10
申请人： Yun-Ju He , Shang-Li Wu , Wei He
发明人： Yun-Ju He , Shang-Li Wu , Wei He
IPC分类号： A61B19/02 , A61M5/00 , A61M5/32 , B01L9/06 , B65D71/00
CPC分类号： A61M5/3205 , A61M5/002 , B01L9/06 , A61B2050/0056 , A61B50/3001 , A61B50/362 , Y10S220/908 , Y10S229/921
摘要： An assembly for housing medical supplies and for storing and mailing medical waste contained therein having an exterior box made of corrugated paper into which a plastic removable medical waste container can be inserted into and secured in a container bay provided by styrofoam insulation which contacts the interior sidewalls of the exterior box. The styrofoam insulation is provided with a plurality of apertures to accommodate syringes. Upon using the syringes, a user can place the syringe through an aperture in the medical waste container. Upon using all of the syringes originally provided with the assembly and placing them inside the medical waste container, the aperture provided in the medical waste container is latched closed and the medical waste container is placed inside the exterior box in the bay provided by the styrofoam insulation. The exterior box is then closed by closing the foldable top of the exterior box and inserting flaps attached to the foldable top to insertion holes provided at the front side of the exterior box. A pair of folded and bent appendages centrally located on the foldable top are inserted into accommodating holes located in the front of the exterior box so as to permanently lock the exterior box such that it cannot be opened without destroying the lock system. The assembly is then mailed to an appropriate disposal sight for incineration.
摘要翻译：一种用于容纳医疗用品并用于存储和邮寄包含在其中的医疗废物的组件，其具有由波纹纸制成的外部盒，塑料可移除医疗废物容器可以插入其中并被固定在由发泡胶绝缘体提供的容器隔室中，所述容器隔间与内侧壁接触的外箱。聚苯乙烯泡沫塑料绝缘体设置有多个孔以容纳注射器。在使用注射器时，用户可以将注射器放置在医疗废物容器中的孔中。在使用最初设置有组件的所有注射器并将其放置在医疗废物容器内时，设置在医疗废物容器中的孔被闭锁，并且医疗废物容器被放置在由发泡胶绝缘体提供的隔间内的外部箱体内。然后通过关闭外部箱的可折叠顶部并将附接到可折叠顶部的折板插入设置在外部箱的前侧的插入孔来关闭外部箱。中心位于可折叠顶部的一对折叠和弯曲的附属物被插入位于外部箱体前部的容纳孔中，以便永久地锁定外部箱体，使得其不会在不破坏锁定系统的情况下打开。然后将该议会邮寄到适当的处理场所进行焚烧。

85. 发明申请

US20170065594A1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS 有权
标题翻译：作为BRUTON酪氨酸激酶抑制剂的多氟化合物
公开(公告)号：US20170065594A1
公开(公告)日：2017-03-09
申请号：US15356014
申请日：2016-11-18
申请人： Wei He
发明人： Wei He
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , C07C303/38 , C07C311/08 , C07D487/04 , C07D519/00 , C07F5/025 , C07F5/04
摘要： Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.
摘要翻译：本文描述了一系列新的多氟取代的吡唑并嘧啶化合物或其盐。这些化合物是Bruton的酪氨酸激酶（BTK）抑制剂。这些化合物可具有更好的BTK抑制选择性和药代动力学性质。本文公开了这些化合物的合成方法。本文公开了多氟取代的二苯甲酮和取代的苯氧基苯的新型合成方法。还公开了包含本文所述的BTK抑制剂的药物组合物。本发明还涉及包含本文所述的化合物作为活性成分的药物制剂。本发明还包括通过施用BTK抑制剂及其制剂来治疗和抑制自身免疫性疾病，超敏反应性疾病，炎性疾病和癌症的治疗方法。

86. 发明授权

US09079861B2 Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 有权
标题翻译： 11＆bgr-羟基类固醇脱氢酶的环状尿素抑制剂1
公开(公告)号：US09079861B2
公开(公告)日：2015-07-14
申请号：US12745663
申请日：2008-11-07
申请人： Salvacion Cacatian , David A. Claremon , Wei He , Suresh B. Singh , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Wei Zhao , Linghang Zhuang
发明人： Salvacion Cacatian , David A. Claremon , Wei He , Suresh B. Singh , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Wei Zhao , Linghang Zhuang
IPC分类号： A61K31/535 , A61K31/505 , C07D239/10 , C07D401/04 , C07D401/10 , C07D403/06 , C07D409/04 , C07D409/10 , C07D417/10
CPC分类号： C07D239/10 , C07D401/04 , C07D401/10 , C07D403/06 , C07D409/04 , C07D409/10 , C07D417/10
摘要： This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih)1 (Ij), (Ik), (Il1-3). (Im1-3), (In1-3), (Io1-2), (Ip1-6), (Iq1-6), (Ir1-6) and (Is1-2), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
摘要翻译：本发明涉及式（I），（Ia），（Ib），（Ic），（Id），（Ie），（If），（Ig），（Ih） Ik），（Il1-3）。（I1-3），（Ⅰ1-3），（Io1-2），（Ⅰp1-6），（Ⅰq1-6），（Ir1-6）和（Is1-2），其药学上可接受的盐，其可用于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病的治疗。本发明进一步涉及新化合物的药物组合物及其用于减少或控制细胞中皮质醇的产生或抑制细胞中可的松转化为皮质醇的方法。

87. 发明授权

US08895935B2 High efficiency secondary and back scattered electron detector 有权
标题翻译：高效二次和背散射电子检测器
公开(公告)号：US08895935B2
公开(公告)日：2014-11-25
申请号：US13417404
申请日：2012-03-12
申请人： Zhibin Wang , Wei He , Qingpo Xi , Shuai Li , Fumin He
发明人： Zhibin Wang , Wei He , Qingpo Xi , Shuai Li , Fumin He
IPC分类号： G01T1/20
CPC分类号： G01T1/20 , H01J37/244 , H01J37/28 , H01J2237/2443 , H01J2237/24475 , H01J2237/2448
摘要： An assembly for a charged particle detection unit is described. The assembly comprises a scintillator disc, a partially coated light guide a thin metal tube for allowing the primary charged particle beam to pass through and a photomultiplier tube (PMT). The shape of scintillator disc and light guide are redesigned to improved the light signal transmission thereafter enhance the light collection efficiency. A light guide with a conicoidal surface over an embedded scintillator improved the light collection efficiency of 34% over a conventional design.
摘要翻译：描述了带电粒子检测单元的组件。组件包括闪烁体盘，部分涂覆的光导，用于允许初级带电粒子束通过的薄金属管和光电倍增管（PMT）。闪烁体盘和光导的形状被重新设计，以改善光信号传输，从而提高光的收集效率。在嵌入式闪烁体上具有锥形表面的导光体比常规设计提高了34％的光收集效率。

88. 发明授权

US08846655B2 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators 有权
标题翻译： 4-取代-2-苯氧基 - 苯胺δ阿片样物质受体调节剂
公开(公告)号：US08846655B2
公开(公告)日：2014-09-30
申请号：US13503433
申请日：2010-10-28
申请人： Steven J. Coats , Haiyan Bian , Chaozhong Cai , Bart L. DeCorte , Li Liu , Mark J. Macielag , Scott L. Dax , Philip M. Pitis , Peter J. Connolly , Wei He
发明人： Steven J. Coats , Haiyan Bian , Chaozhong Cai , Bart L. DeCorte , Li Liu , Mark J. Macielag , Scott L. Dax , Philip M. Pitis , Peter J. Connolly , Wei He
IPC分类号： A61K31/40 , A61K31/445 , A61K31/4439 , A61K31/4025 , A61K31/506 , A61K31/495 , C07D211/56 , C07D405/12 , C07D207/09 , C07C255/50 , C07C211/48 , C07D413/12 , C07D401/12 , C07C211/50 , C07D205/04 , C07C233/08 , C07C233/11 , C07C233/65 , C07D451/04 , C07D453/02 , C07D409/12
CPC分类号： C07D401/12 , C07C211/48 , C07C211/50 , C07C233/08 , C07C233/11 , C07C233/65 , C07C255/50 , C07D205/04 , C07D207/09 , C07D211/56 , C07D405/12 , C07D409/12 , C07D413/12 , C07D451/04 , C07D453/02
摘要： Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R1, R2, R3, Ra, and Y are defined herein.
摘要翻译：公开了用于治疗各种疾病，综合征，病症和障碍（包括疼痛）的化合物，组合物和方法。这样的化合物由式I表示如下：其中R1，R2，R3，Ra和Y如本文所定义。

89. 发明授权

US08822482B2 Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof 有权
标题翻译：盐酸伊替替，合成，结晶形式，药物组合物及其用途
公开(公告)号：US08822482B2
公开(公告)日：2014-09-02
申请号：US13003216
申请日：2009-07-07
申请人： Yinxiang Wang , Guojian Xie , Lieming Ding , Fenlai Tan , Yunyan Hu , Wei He , Bin Han , Wei Long , Yong Liu , Haima Ai , Charles Davis , Don Zhang
发明人： Yinxiang Wang , Guojian Xie , Lieming Ding , Fenlai Tan , Yunyan Hu , Wei He , Bin Han , Wei Long , Yong Liu , Haima Ai , Charles Davis , Don Zhang
IPC分类号： A61K31/519 , C07D491/056
CPC分类号： C07D491/056 , A61K31/519 , C07B2200/13
摘要： The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
摘要翻译：本发明涉及4 - [（3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐，其新结晶形式，其用于治疗由EGFR激酶介导的疾病及其组合治疗用途的治疗用途与其他治疗剂。本发明还提供用于制备4 - [（3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐的合成方法，其新结晶形式和用于合成4 - [（ -3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐。

90. 发明授权

US08748444B2 Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 有权
标题翻译： 11＆bgr-羟基类固醇脱氢酶的环状尿素抑制剂1
公开(公告)号：US08748444B2
公开(公告)日：2014-06-10
申请号：US13873574
申请日：2013-04-30
申请人： Salvacion Cacatian , David A. Claremon , Wei He , Suresh B. Singh , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Wei Zhao , Linghang Zhuang
发明人： Salvacion Cacatian , David A. Claremon , Wei He , Suresh B. Singh , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Wei Zhao , Linghang Zhuang
IPC分类号： C07D239/10
CPC分类号： C07D239/10 , C07D239/42 , C07D265/10 , C07D401/12 , C07D413/12
摘要： Disclosed are compounds represented by Formula (I): or pharmaceutically acceptable salts, enantiomers or diastereomers thereof. Also disclosed are pharmaceutical compositions comprising the compounds of Formula (I) or pharmaceutically acceptable salts, enantiomers or diastereomers thereof and methods of inhibiting 11 β-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (I) or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Values for the variables of Formula (I) are defined herein.
摘要翻译：公开了由式（I）表示的化合物或其药学上可接受的盐，对映异构体或非对映异构体。还公开了包含式（I）化合物或其药学上可接受的盐，对映异构体或非对映异构体的药物组合物和抑制11β-HSD1活性的方法，其包括向需要这种治疗的哺乳动物施用有效量的式（I）化合物或其药学上可接受的盐，对映体或非对映异构体。式（I）的变量的值在本文中定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式